Menu
Search
|

Menu

Close
X

Rocket Pharmaceuticals Inc RCKT.OQ (NASDAQ Stock Exchange Global Market)

12.25 USD
-0.50 (-3.92%)
As of Jul 23
Previous Close 12.75
Open 12.84
Volume 69,697
3m Avg Volume 108,991
Today’s High 12.84
Today’s Low 12.21
52 Week High 25.85
52 Week Low 10.75
Shares Outstanding (mil) 50.29
Market Capitalization (mil) 641.19
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.38 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.431
FY18
-1.882
FY17
-2.881
FY16
-1.442
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.39
Price to Sales (TTM)
vs sector
--
8.16
Price to Book (MRQ)
vs sector
3.25
4.43
Price to Cash Flow (TTM)
vs sector
--
24.27
Total Debt to Equity (MRQ)
vs sector
23.89
17.60
LT Debt to Equity (MRQ)
vs sector
23.89
12.56
Return on Investment (TTM)
vs sector
-36.45
12.67
Return on Equity (TTM)
vs sector
-45.29
17.18

EXECUTIVE LEADERSHIP

Roderick Wong
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Gaurav Shah
President, Chief Executive Officer, Director, Since 2018
Salary: $413,735.00
Bonus: $300,940.00
John Militello
Principal Financial Officer, Principal Accounting Officer, Controller, Since 2018
Salary: --
Bonus: --
Kinnari Patel
Chief Operating Officer and Head of Development, Since 2018
Salary: $358,864.00
Bonus: $198,093.00
Jonathan Schwartz
Chief Medical Officer, Since 2018
Salary: $359,820.00
Bonus: $157,241.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

350 5th Ave Ste 7530
NEW YORK   NY   10118-7501

Phone: +1646.4409100

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapy treatment options for rare, devastating diseases. The Company’s multi-platform development approach applies the well-established lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The Company’s lead clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a genetic disease that leads to bone marrow failure and potentially cancer. Its additional pipeline programs for bone marrow-derived disorders are for Pyruvate Kinase Deficiency (PKD), Leukocyte Adhesion Deficiency-I (LAD-I) and Infantile Malignant Osteopetrosis (IMO). The Company is also developing an AAV-based gene therapy program for pediatric heart failure indication, Danon disease.

SPONSORED STORIES